Toviaz Related Published Studies
Well-designed clinical trials related to Toviaz (Fesoterodine)
Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder. [2011.11]
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladder. [2011.05]
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. [2011.05]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2011.05]
Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. [2010.09.21]
Thorough QT study of the effect of fesoterodine on cardiac repolarization. [2010.05]
Efficacy and tolerability of fesoterodine in men with overactive bladder: a pooled analysis of 2 phase III studies. [2010.05]
Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. [2010.05]
Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. [2010.04]
Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms. [2010.04]
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. [2010.02]
Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial. [2010.01]
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine in subjects with overactive bladder. [2010.01]
Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects
with overactive bladder symptoms. [2010]
Fesoterodine in patients with overactive bladder syndrome: can the severity of
baseline urgency urinary incontinence predict dosing requirement? [2010]
Comparison of fesoterodine and tolterodine extended release for the treatment of
overactive bladder: a head-to-head placebo-controlled trial. [2010]
Efficacy of fesoterodine over 24 hours in subjects with overactive bladder. [2010]
Efficacy and tolerability of fesoterodine in men with overactive bladder: a
pooled analysis of 2 phase III studies. [2010]
Response to fesoterodine in patients with an overactive bladder and urgency
urinary incontinence is independent of the urodynamic finding of detrusor
overactivity. [2010]
Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine. [2009.09]
Efficacy and tolerability of fesoterodine in women with overactive bladder. [2009.07]
Influence of food on the pharmacokinetic profile of fesoterodine. [2009.06]
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine. [2009.03.07]
Pharmacokinetic profile of fesoterodine. [2008.11]
Comparison of fesoterodine and tolterodine in patients with overactive bladder. [2008.11]
Impact of fesoterodine on quality of life: pooled data from two randomized trials. [2008.07]
Fesoterodine dose response in subjects with overactive bladder syndrome. [2008.05]
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. [2007.12]
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. [2007.10]
Well-designed clinical trials possibly related to Toviaz (Fesoterodine)
Which anticholinergic drug for overactive bladder symptoms in adults. [2012]
Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? [2011.07]
Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model. [2011.05.20]
Other research related to Toviaz (Fesoterodine)
Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence:
a double-blind, placebo controlled trial. [2014]
Effect of fesoterodine on urethral closure function in women with stress urinary
incontinence assessed by urethral pressure reflectometry. [2014]
Evaluation of fesoterodine fumarate for the treatment of an overactive bladder. [2013]
Sustained improvement in patient-reported outcomes during long-term fesoterodine treatment for overactive bladder symptoms: pooled analysis of two open-label extension studies. [2011.11.30]
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving alpha-blocker treatment for lower urinary tract symptoms. [2011.10.03]
Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects. [2011.08]
Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. [2011.03]
Early onset of fesoterodine efficacy in subjects with overactive bladder. [2011.02]
Patient-optimized doses of fesoterodine improve bladder symptoms in an open-label, flexible-dose study. [2011.02]
Review of fesoterodine. [2011]
Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder. [2010.12]
Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement? [2010.09]
Modeling dose-response relationships of the effects of fesoterodine in patients with overactive bladder. [2010.08.19]
Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. [2010.08]
The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service. [2010.08]
Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. [2010.07]
Fesoterodine fumarate. [2010.02]
Thorough QT study of the effect of fesoterodine on cardiac repolarization. [2010]
Randomized, double-blind, placebo-controlled trial of flexible-dose fesoterodine
in subjects with overactive bladder. [2010]
The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime
dosing. [2010]
Fesoterodine for the treatment of overactive bladder. [2009.12]
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. [2009.04]
Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine. [2009.04]
Fesoterodine: a new agent for treating overactive bladder. [2009.03]
Darunavir: a review of its use in the management of HIV infection in adults. [2009]
Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. [2008.07]
Other possibly related research studies
Overactive Bladder Drugs and Constipation: A Meta-Analysis of Randomized, Placebo-Controlled Trials. [2010.07.02]
Tolterodine extended-release for overactive bladder. [2009.09]
[Anticholinergic treatment of overactive bladder syndrome. Is it all the same?] [2009.03]
Muscarinic receptor antagonists for overactive bladder treatment: does one fit all? [2009.01]
Gateways to clinical trials. [2008.06]
The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. [2008.09]
Gateways to clinical trials. [2007.11]
Update on the treatment of overactive bladder. [2011.07]
Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. [2011.02.23]
Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. [2011.04]
Gateways to clinical trials. [2010.07]
Overactive bladder drugs and constipation: a meta-analysis of randomized, placebo-controlled trials. [2011.01]
Benefits and harms of pharmacologic treatment for urinary incontinence in women:
a systematic review. [2012]
Long-term efficacy and safety of questionnaire-based initiation of urgency
urinary incontinence treatment. [2013]
|